Endevica Bio Announces First Patient Dosing in Phase 2 Trial in Patients with Stage 4 Metastatic Colorectal Cancer

On April 30, 2025 Endevica Bio, a privately held company developing first-in-class peptide drug candidates, reported the dose administration for the first patient in a Phase 2 trial for its experimental drug TCMCB07 (B07) to prevent weight loss in cancer patients undergoing chemotherapy (Press release, Endevica Bio, APR 30, 2025, View Source [SID1234652383]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The trial, being conducted in partnership with WuXi Clinical, will include 20 sites and 100 patients who are diagnosed with stage 4 metastatic colorectal cancer.

In the trial, patients are dosed with B07 as they begin chemotherapy and during the first several rounds of chemotherapy. The primary endpoint is preventing weight loss, which can lead to a debilitating condition called cachexia, a life-threatening wasting syndrome associated with chronic diseases, including cancer.

"This marks an important milestone in our commitment in developing a potentially life changing treatment for cachexia," said Russell Potterfield, Chief Executive Officer and Executive Chair of Endevica. "Each trial brings us closer to offering a viable solution for this debilitating disease, and we remain dedicated to making a lasting impact on the lives of those affected."

"We are incredibly excited to have our first patient dosed with B07 in individuals diagnosed with metastatic colorectal cancer who are undergoing chemotherapy," said Dr. Daniel Marks, Chief Medical and Scientific Officer of Endevica Bio. "Since there is no FDA approved therapeutic for cancer cachexia, this trial is a crucial step to provide a therapy for an area of huge unmet clinical need, and we look forward to the results."

In 2024, Endevica Bio completed its Phase 1 clinical trial with preliminary findings supporting its strong safety and efficacy. Last November, the Journal of Clinical Investigation, showed that B07 improved the appetite and preserved lean mass and fat mass in rodent models of cancer and its associated combination chemotherapy. This same study showed the strong potential of B07 to alleviate chemotherapy-induced anorexia and weight loss for millions of patients worldwide.

About TCMCB07
TCMCB07 is a melanocortin‐3/4 antagonist peptide candidate in clinical development for the treatment of cachexia. It is designed to be a first-in-class peptide drug with the ability to cross the blood-brain barrier and act on previously inaccessible target receptors to modulate the body’s behavioral and metabolic response to chronic illness. Pre-clinical animal trial results show significant lean muscle mass retention (e.g., a reversal of the cachectic condition) during administration of the drug. The results are consistent in cachexia arising from many different types of chronic disease.

J INTS BIO Presents Research Results for Next-Generation Innovative Anticancer Therapeutics ‘JIN-A02’ and ‘JIN-001’ at AACR 2025

On April 30, 2025 J INTS BIO, a company specializing in anticancer and orphan drugs, reported its research findings for the next-generation EGFR-TKI therapeutic ‘JIN-A02’ (clinical Phase 1/2 results) and the ovarian cancer treatment candidate ‘JIN-001’ (preclinical results) at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) 2025, held in Chicago from April 25 to 30 (Press release, J INTS BIO, APR 30, 2025, View Source [SID1234652400]). In this presentation, J INTS BIO demonstrated its innovative drug development capabilities on a global stage, attracting significant attention from both academia and the industry.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

‘JIN-A02’: New Hope for Overcoming Resistance – 4th Generation EGFR-TKI Clinical Results

Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancer cases worldwide, and among these, EGFR mutations are considered a major therapeutic target. JIN-A02, introduced at AACR (Free AACR Whitepaper) 2025, showed outstanding therapeutic efficacy in patients who developed resistance to existing third-generation EGFR-TKIs. In particular, JIN-A02 demonstrated remarkable antitumor activity in patients with EGFR C797S mutation—currently a mutation for which no approved targeted therapies exist—thus opening a new avenue for treatment options.

In the clinical trial, a patient in the 300 mg cohort showed complete clearance of circulating tumor DNA (ctDNA) harboring either the C797S or Ex19del mutation, and ctDNA carrying the T790M mutation was reduced by over 90%. Clinically, a partial response (PR) was observed, with tumor size reductions of up to 39.7%, and notable shrinkage of intracranial metastatic lesions. These findings are particularly important for NSCLC patients, in whom brain metastases are common. Furthermore, no dose-limiting toxicities (DLTs) or serious adverse events were observed up to the 300 mg dose, highlighting the excellent safety profile of JIN-A02. This safety profile is expected to be particularly beneficial for patients requiring long-term treatment and combination therapies.

Currently, JIN-A02 is undergoing multinational clinical trials in Korea, the United States, Thailand, and other countries, and it is being closely watched as a potential groundbreaking treatment option for EGFR-mutant NSCLC patients.

‘JIN-001’: An Innovative New Drug Targeting Refractory Ovarian Cancer

Also presented was ‘JIN-001,’ J INTS BIO’s second-generation synthetic HSP90 inhibitor, developed as a new strategy to overcome resistance to existing ovarian cancer treatments. Ovarian cancer remains one of the deadliest gynecological malignancies, as it is often diagnosed at an advanced stage when effective treatment options are extremely limited.

The preclinical study demonstrated that JIN-001, when combined with the chemotherapeutic agent cisplatin, significantly enhanced tumor suppression compared to cisplatin alone. Notably, even at low concentrations (≤0.1 μM), JIN-001 enhanced the antitumor activity of cisplatin against both cisplatin-sensitive and cisplatin-resistant ovarian cancer cells, compared to cisplatin alone. Moreover, the combination therapy significantly reduced the expression of key signaling proteins related to cisplatin resistance, contributing to a sustained antitumor effect.

Based on these promising results, J INTS BIO is planning additional preclinical studies and aims to rapidly advance JIN-001 into clinical trials, with the goal of establishing a new standard of care for the treatment of refractory and multidrug-resistant ovarian cancer.

Led by the presentation at AACR (Free AACR Whitepaper) 2025, J INTS BIO aims to further strengthen its competitiveness in the global oncology market and solidify its position as a frontrunner in next-generation anticancer drug development. The company also outlined its vision to continue delivering innovative therapies through ongoing research and development efforts, offering new hope to cancer patients worldwide.

FORE Biotherapeutics to Present Plixorafenib Abstract at the 2025 American Society of Clinical Oncology Annual Meeting

On April 30, 2025 FORE Biotherapeutics, a registration stage biotherapeutics company dedicated to developing targeted therapies to treat patients with cancer, reported that a plixorafenib abstract has been selected for poster presentation at the 2025 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting (ASCO) (Free ASCO Whitepaper), taking place May 30-June 3, 2025 in Chicago (Press release, Fore Biotherapeutics, APR 30, 2025, View Source [SID1234652384]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

At ASCO (Free ASCO Whitepaper) 2025, Karisa Schreck, M.D., Ph.D., from the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, will present a trials-in-progress poster highlighting the study design of the global registration-intended FORTE Master Protocol, which includes four sub-protocol baskets evaluating plixorafenib in distinct patient populations. The three monotherapy indications currently under evaluation are BRAF V600 Recurrent Primary Central Nervous System Tumors, Rare BRAF V600 Mutated Solid Tumors and Solid Tumors with BRAF Fusions.

Poster Presentation Details:

Title: FORTE: A phase 2 master protocol assessing plixorafenib for BRAF-altered cancers
Poster Session: Central Nervous System Tumors
Date and Time: Saturday, May 31, 2025, 9:00 a.m. – 12:00 p.m. CT
Abstract Number: TPS2091
Presenter: Karisa Schreck, M.D., Ph.D., Johns Hopkins University

Ingenium Therapeutics Receives FDA Feedback Enabling Direct Phase 2 Trial for Gengleucel in MRD+ AML

On April 30, 2025 Ingenium Therapeutics, a clinical-stage biotechnology company advancing allogeneic natural killer (NK) cell therapies, reported that it has received positive regulatory feedback from the U.S. Food and Drug Administration (FDA) following a Pre-Investigational New Drug (Pre-IND) meeting (Press release, Ingenium Therapeutics, APR 30, 2025, View Source [SID1234652401]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Ingenium has conducted multiple investigator-initiated trials in South Korea, enrolling over 140 patients with acute myeloid leukemia (AML), including a Phase 2 randomized clinical trial with long-term overall survival follow-up. These studies have generated robust non-clinical and clinical data supporting the safety and efficacy profile of Gengleucel.

Based on its review of these data, the FDA has provided positive feedback on Ingenium’s proposal to initiate a Phase 2 trial of Gengleucel in the United States without a preceding Phase 1 study. This regulatory milestone may streamline Gengleucel’s clinical development pathway and may accelerate access for patients with measurable residual disease-positive (MRD+) AML.

The planned multicenter study will be conducted at leading cancer centers across the United States, including a world-renowned institution in Texas. Gengleucel is positioned to become the first NK cell therapy in AML to use MRD negativity as a primary endpoint, underscoring its potential to improve outcomes by eradicating minimal residual disease and reducing relapse risk.

"We are thrilled with the FDA’s guidance, which reflects the rigor of our clinical research and the significant therapeutic potential of Gengleucel, especially in targeting minimal residual disease," said Kevin Koh, CEO of Ingenium Therapeutics. "Launching our U.S. Phase 2 trial at premier cancer centers marks a major milestone in our mission to deliver novel immunotherapies to AML patients with MRD."

The trial is expected to begin in early 2026 and will evaluate Gengleucel’s ability to achieve MRD negativity and reduce relapse and mortality. To ensure reliable clinical operations and product supply, Ingenium is transferring its manufacturing technology to a Texas-based manufacturing facility.

About Gengleucel

Gengleucel is a non-engineered, allogeneic NK cell therapy composed of memory NK cells with enhanced activating receptor expression and increased secretion of IFN-gamma, granzyme, and perforin. These features drive potent anti-cancer activity and sustained in vivo persistence. Clinical trials have demonstrated Gengleucel’s favorable safety, tolerability, and efficacy in high-risk AML and MDS populations. Gengleucel has been granted Orphan Drug Designation by the U.S. FDA for the treatment of AML.

Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Ras Inhibitor Resistant Lung Cancer at the 2025 AACR Annual Meeting

On April 30, 2025 Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, reported that its research collaborators presented positive preclinical data for Reqorsa Gene Therapy (quaratusugene ozeplasmid), for the treatment of KRASG12C mutant non-small cell lung cancer (NSCLC) (Press release, Genprex, APR 30, 2025, View Source [SID1234652385]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This data were presented at the 2025 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting being held April 25-30, 2025 in Chicago, Illinois.

"We are pleased to have this positive preclinical data presented before an audience of the world’s leading cancer researchers, which provides further support for the therapeutic potential of REQORSA both alone and in combination with targeted therapies in NSCLC," said Ryan Confer, President and Chief Executive Officer at Genprex. "We believe REQORSA could be a potential therapeutic treatment for Ras inhibitor resistant lung cancer either alone or in combination with Ras inhibitors, and these studies support the potential expansion of future clinical studies in our pipeline."

The featured Genprex-supported poster presented at AACR (Free AACR Whitepaper) 2025:

Title: Overcoming sotorasib acquired resistance in KRASG12C mutant NSCLC by TUSC2 gene therapy

Session Category: Experimental and Molecular Therapeutics

Session Title: Drug Resistance in Molecular Targeted Therapies 3

Session Date and Time: Tuesday, April 29 from 2-5 p.m. CT

Location: Poster Section 17

Poster Board Number: 12

Abstract Presentation Number: 5517

In the poster, entitled, "Overcoming sotorasib acquired resistance in KRASG12C mutant NSCLC by TUSC2 gene therapy," researchers demonstrated that TUSC2 gene therapy (REQORSA) effectively overcomes sotorasib (LUMAKRAS) acquired resistance (AR) in KRASG12C mutant NSCLC mouse xenografts. The data indicate that TUSC2 transfection significantly reduced colony formation and markedly increased apoptosis in two AR cell lines. Re-expression of TUSC2 in AR PDXOs significantly decreased the viability of organoids compared with the empty vector. The H23AR tumors exhibited significantly lower sensitivity to sotorasib than their parental counterparts. However, treatment with REQORSA was highly effective in controlling tumor growth compared to treatment with sotorasib alone or the control groups. REQORSA alone also exhibited a strong antitumor effect on TC314AR PDXs. Sotorasib alone showed no significant antitumor activity in these models. However, a synergistic antitumor effect was observed when TC314AR PDX tumors were treated with the combination of REQORSA and sotorasib. In conclusion, researchers demonstrated that REQORSA, alone or in combination with sotorasib, induced apoptosis, inhibited colony formation, and showed significant antitumor efficacy in KRASG12C mutant sotorasib-acquired resistant xenograft and PDX tumors.

This AACR (Free AACR Whitepaper) poster has been made available on Genprex’s website at www.genprex.com.

About Reqorsa Gene Therapy

REQORSA (quaratusugene ozeplasmid) consists of a plasmid containing the TUSC2 gene encapsulated in non-viral lipid-based nanoparticles in a lipoplex form (the Company’s Oncoprex Delivery System), which has a positive charge. REQORSA is injected intravenously and specifically targets cancer cells. REQORSA is designed to deliver the functioning TUSC2 gene to negatively charged cancer cells while minimizing uptake by normal tissue. Laboratory studies conducted at MD Anderson show that the uptake of TUSC2 in tumor cells in vitro after REQORSA treatment was 10 to 33 times the uptake in normal cells.